Ambit, formerly known as Aventa Biosciences, has hired investment banks Citigroup and Leerink Swann for its $57.5m initial public offering (IPO) after raising more than $165m.
Ambit Biosciences, a US-based anti-cancer drugs developer backed by peers Roche and AstraZeneca’s (AZ) corporate venturing units, has restarted plans to float on the Nasdaq stock exchange, according to a regulatory filing first seen by news provider Fierce Biotech.
Ambit, formerly known as Aventa Biosciences, has hired investment banks Citigroup and Leerink Swann for its $57.5m initial public offering (IPO) after raising more than $165m.
Ambit said in its regulatory filing that its shareholders have agreed to buy shares…
